

# Rubi K Li

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3662643/publications.pdf>

Version: 2024-02-01

7  
papers

445  
citations

1684188

5  
h-index

1720034

7  
g-index

7  
all docs

7  
docs citations

7  
times ranked

766  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study. <i>BioDrugs</i> , 2022, 36, 55-69.	4.6	7
2	Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations. <i>International Journal of Clinical Oncology</i> , 2021, 26, 841-850.	2.2	2
3	Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 631-640.	2.5	11
4	NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2â€³, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2019, 20, 1148-1159.	10.7	288
5	PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study. <i>British Journal of Cancer</i> , 2019, 120, 172-182.	6.4	43
6	CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. <i>Lancet Oncology</i> , The, 2017, 18, 917-928.	10.7	93
7	Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC): Asian subgroup analysis.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7549-7549.	1.6	1